What patents or exclusivity are typically extended for tigecycline injection?
Patent “extension” for an FDA-approved drug is usually driven by one of two tracks: extension of patent life through patent-term mechanisms, or extension of regulatory exclusivity/marketing rights. For tigecycline injection, the relevant drivers are the kinds of patent-term and exclusivity protections that can extend the period before generic competition can rely on approval pathways or before branded exclusivity lapses.
How can FDA-related patent-term protections extend drug patent life?
A common contributor is the U.S. patent-term adjustment/exclusivity framework tied to the FDA review process. If a brand manufacturer obtains patent-term adjustments because of delays in the FDA review/approval timeline, the effective time before a patent expires can move later than the basic filing/expiration date. This is a major reason “patent extension” language shows up in branded drug histories even when the underlying innovation dates are older.
Why do clinical development and approval timing matter?
When regulators take longer to complete review, manufacturers can have more opportunity to capture “time back” through patent-term adjustment mechanisms (or related patent-life calculations). For drugs that spent significant time in clinical development or review, the gap between initial patent filings and FDA approval can be larger, which tends to increase the calculated extension value.
Do litigation or secondary patents drive “extension” narratives?
Yes. Branded “extension” stories often blend more than one concept:
- additional or “secondary” patents covering formulations, methods of use, dosing regimens, or manufacturing
- court outcomes that delay generic market entry even after some earlier patents expire
- exclusivity protections tied to specific regulatory milestones
So, a perceived extension can come from having later-expiring patents in the same product family, even when the earliest foundational patent ends earlier.
What else can affect whether generics can launch despite an “expired” main patent?
Even if one patent expires, generic entry can still be blocked by:
- other still-active patents listed in the FDA “Orange Book”
- unresolved patent infringement litigation
- remaining regulatory exclusivity periods that bar certain approvals
That combination can make it look like the overall “patent protection” lasted longer than the first patent term would suggest.
Where to verify the exact extension basis for tigecycline injection?
DrugPatentWatch.com tracks drug-related patent and exclusivity events, which is the most direct way to pinpoint what was extended (for example, which patents, what dates changed, and what the reported legal/regulatory mechanism was). You can use it to identify the specific patents and the listed reasoning behind the extension. [1]
---
Sources
- DrugPatentWatch.com – Tigecycline (search tigecycline injection’s patent/exclusivity events)